Co-Authors
This is a "connection" page, showing publications co-authored by Michael Liptay and Jeffrey Borgia.
Connection Strength
2.518
-
Establishment of a multi-analyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer. J Thorac Oncol. 2009 Mar; 4(3):338-47.
Score: 0.334
-
Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with 'Actionable' Pulmonary Nodules. Cancers (Basel). 2023 Apr 12; 15(8).
Score: 0.222
-
The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer. Oncotarget. 2022; 13:393-407.
Score: 0.205
-
Circulating histocompatibility antigen (HLA) gene products may help differentiate benign from malignant indeterminate pulmonary lesions. Hum Immunol. 2018 Jul; 79(7):558-563.
Score: 0.157
-
Development of bead based multiplexed immunoassay for evaluation of midkine, syndecan-1, and ANGPTL4 in patient serum. J Immunoassay Immunochem. 2018; 39(1):84-98.
Score: 0.155
-
Reply. Ann Thorac Surg. 2018 07; 106(1):316-317.
Score: 0.154
-
Serum Biomarkers May Prognosticate Recurrence in Node-Negative, Non-Small Cell Lung Cancers Less Than 4 Centimeters. Ann Thorac Surg. 2017 Nov; 104(5):1637-1643.
Score: 0.151
-
Angiogenesis Biomarkers May Be Useful in the Management of Patients With Indeterminate Pulmonary Nodules. Ann Thorac Surg. 2015 Aug; 100(2):429-36.
Score: 0.130
-
Circulating angiogenesis biomarkers are associated with disease progression in lung adenocarcinoma. Ann Thorac Surg. 2014 Dec; 98(6):1968-75; discussion 1975.
Score: 0.123
-
Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2015 Mar; 149(3):727-34.e1-3; discussion 734.
Score: 0.123
-
Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules. J Thorac Oncol. 2013 Jan; 8(1):31-6.
Score: 0.109
-
Development of a serum biomarker panel predicting recurrence in stage I non-small cell lung cancer patients. J Thorac Cardiovasc Surg. 2012 Dec; 144(6):1344-50; discussion 1350-1.
Score: 0.107
-
Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg. 2011 Nov; 92(5):1805-11; discussion 1811.
Score: 0.100
-
Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers. Int J Cancer. 2011 Jul 01; 129(1):133-42.
Score: 0.094
-
A multi-analyte serum test for the detection of non-small cell lung cancer. Br J Cancer. 2010 Oct 12; 103(8):1221-8.
Score: 0.093
-
Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010 Jul 01; 16(13):3452-62.
Score: 0.091
-
The association between thoracic sarcopenia and survival is gender specific in early-stage lung cancer. J Thorac Dis. 2022 Nov; 14(11):4256-4265.
Score: 0.054
-
Sarcopenia after induction therapy is associated with reduced survival in patients undergoing esophagectomy for locally-advanced esophageal cancer. J Thorac Dis. 2021 Feb; 13(2):861-869.
Score: 0.048
-
Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2016 Jul; 152(1):55-61.e1.
Score: 0.034
-
Evaluation of Plasma miR-21 and miR-152 as Diagnostic Biomarkers for Common Types of Human Cancers. J Cancer. 2016; 7(5):490-9.
Score: 0.034